Cundong Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Cundong Liu has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
Cheng Yang
21 shared publicationsHu Tian
Department of Urology The Third Affiliated Hospital of Southern Medical University Guangzhou China
15 shared publicationsQi Chen
The Third Affiliated Hospital of Southern Medical University
10 shared publicationsRanran Zhou
9 shared publicationsHui Xia
8 shared publicationsJun-Hao Zhou
Department of Urology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China
8 shared publications
Latest Publications
- Open Access
Pentachlorophenol enhances bladder cancer cell invasion through altered protein stability
- Open Access
- 1 August 2026
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 15 (8) , 312
Initial experience and technical description of robot-assisted single-port laparoscopic bilateral inguinal lymph node dissection for penile cancer: a report of two cases
Background: Penile cancer is a rare malignancy of the urogenital system with a well-defined lymphatic metastatic pathway. Inguinal lymph node dissection remains the cornerstone for managing lymph node metastasis in penile cancer and can effectively control disease spread. However, conventional open surgery is associated with a high rate of complications, including skin necrosis, infection, and lymphedema, and the substantial surgical trauma limits its widespread clinical use. To reduce invasiveness, we introduce a novel surgical approach designed to enhance dissection accuracy and completeness. This study aims to evaluate the feasibility and safety of robot-assisted single-port laparoscopic bilateral inguinal and pelvic lymph node dissection via a suprapubic antegrade approach. Case Description: We report two cases of penile squamous cell carcinoma treated with this technique. Case 1 was a 61-year-old male presented with a progressively enlarging penile mass with superficial ulceration. Histopathology revealed moderately differentiated squamous cell carcinoma [non-human papillomavirus (HPV)-associated] with lymph node metastasis. The patient first underwent radical penectomy, followed by robot-assisted single-port laparoscopic bilateral inguinal and pelvic lymph node dissection two weeks later. Case 2 was a 53-year-old male presented with penile pain. Preoperative imaging revealed a malignant lesion on the glans penis accompanied by bilateral inguinal lymphadenopathy. The patient underwent immediate radical penectomy combined with robot-assisted single-port laparoscopic bilateral inguinal lymph node dissection. Both patients recovered without major postoperative complications. During follow-up (case 1: 6 months; case 2: 2 months), neither experienced tumor recurrence nor significant adverse events. Conclusions: Our preliminary experience indicates that robot-assisted single-port laparoscopic bilateral inguinal lymph node dissection is technically feasible in this small case series. The technique offers favorable cosmetic outcomes due to the single concealed incision. However, long-term oncologic outcomes require further investigation, and additional studies with larger cohorts and extended follow-up are needed to confirm its clinical effectiveness.
- 1 August 2026
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 15 (8) , 312
Open AccessInitial experience and technical description of robot-assisted single-port laparoscopic bilateral inguinal lymph node dissection for penile cancer: a report of two cases
Background: Penile cancer is a rare malignancy of the urogenital system with a well-defined lymphatic metastatic pathway. Inguinal lymph node dissection remains the cornerstone for managing lymph node metastasis in penile cancer and can effectively control disease spread. However, conventional open surgery is associated with a high rate of complications, including skin necrosis, infection, and lymphedema, and the substantial surgical trauma limits its widespread clinical use. To reduce invasiveness, we introduce a novel surgical approach designed to enhance dissection accuracy and completeness. This study aims to evaluate the feasibility and safety of robot-assisted single-port laparoscopic bilateral inguinal and pelvic lymph node dissection via a suprapubic antegrade approach. Case Description: We report two cases of penile squamous cell carcinoma treated with this technique. Case 1 was a 61-year-old male presented with a progressively enlarging penile mass with superficial ulceration. Histopathology revealed moderately differentiated squamous cell carcinoma [non-human papillomavirus (HPV)-associated] with lymph node metastasis. The patient first underwent radical penectomy, followed by robot-assisted single-port laparoscopic bilateral inguinal and pelvic lymph node dissection two weeks later. Case 2 was a 53-year-old male presented with penile pain. Preoperative imaging revealed a malignant lesion on the glans penis accompanied by bilateral inguinal lymphadenopathy. The patient underwent immediate radical penectomy combined with robot-assisted single-port laparoscopic bilateral inguinal lymph node dissection. Both patients recovered without major postoperative complications. During follow-up (case 1: 6 months; case 2: 2 months), neither experienced tumor recurrence nor significant adverse events. Conclusions: Our preliminary experience indicates that robot-assisted single-port laparoscopic bilateral inguinal lymph node dissection is technically feasible in this small case series. The technique offers favorable cosmetic outcomes due to the single concealed incision. However, long-term oncologic outcomes require further investigation, and additional studies with larger cohorts and extended follow-up are needed to confirm its clinical effectiveness.
- Open Access
Investigating the Shared Mechanisms of Endocrine-Disrupting Chemicals in Urogenital Tumors
Endocrine-disrupting chemicals (EDCs) are important environmental risk factors for urogenital malignancies, but the shared molecular mechanisms underlying their carcinogenic effects remain poorly understood. Here, we systematically investigated the common pro-tumorigenic mechanisms of 12 prevalent EDCs, including anthracene, benzo[a]pyrene (BaP), bisphenol A, clofenotane, di(2-ethylhexyl) phthalate, diazinon, dibutyl phthalate, glyphosate, malathion, perfluorooctanoic acid, polychlorinated biphenyls, and triclosan, across four urogenital cancers, including bladder cancer (BLCA), renal cell carcinoma (RCC), prostate adenocarcinoma (PRAD), and testicular germ cell tumor (TGCT). By integrating network toxicology and protein–protein interaction analysis, we identified shared hub targets linking EDC exposure to tumor progression. EGFR and CASP3 were identified as core targets in BLCA, EGFR and CASP9 in RCC, and CASP3, ESR1, and EGFR in PRAD, whereas KIT emerged as a broadly relevant target in TGCT. Molecular docking and molecular dynamics simulations supported the stable binding of EDCs to these targets. Among the predicted interactions, BaP showed strong binding affinity for CASP9 (ΔG = −9.8 kcal/mol) and was therefore selected for experimental validation. Analysis of TCGA data showed that elevated CASP9 expression was significantly associated with poorer overall survival in patients with RCC. In 786-O and ACHN cells, chronic exposure to an environmentally relevant concentration of BaP significantly increased CASP9 protein stability without altering its mRNA expression, suggesting post-transcriptional regulation. Collectively, these findings identify shared molecular targets of EDCs across urogenital cancers and provide new mechanistic insight into EDC-driven tumor progression, prioritizing potential biomarkers and therapeutic targets for environmentally related malignancies.
Open AccessInvestigating the Shared Mechanisms of Endocrine-Disrupting Chemicals in Urogenital Tumors
Endocrine-disrupting chemicals (EDCs) are important environmental risk factors for urogenital malignancies, but the shared molecular mechanisms underlying their carcinogenic effects remain poorly understood. Here, we systematically investigated the common pro-tumorigenic mechanisms of 12 prevalent EDCs, including anthracene, benzo[a]pyrene (BaP), bisphenol A, clofenotane, di(2-ethylhexyl) phthalate, diazinon, dibutyl phthalate, glyphosate, malathion, perfluorooctanoic acid, polychlorinated biphenyls, and triclosan, across four urogenital cancers, including bladder cancer (BLCA), renal cell carcinoma (RCC), prostate adenocarcinoma (PRAD), and testicular germ cell tumor (TGCT). By integrating network toxicology and protein–protein interaction analysis, we identified shared hub targets linking EDC exposure to tumor progression. EGFR and CASP3 were identified as core targets in BLCA, EGFR and CASP9 in RCC, and CASP3, ESR1, and EGFR in PRAD, whereas KIT emerged as a broadly relevant target in TGCT. Molecular docking and molecular dynamics simulations supported the stable binding of EDCs to these targets. Among the predicted interactions, BaP showed strong binding affinity for CASP9 (ΔG = −9.8 kcal/mol) and was therefore selected for experimental validation. Analysis of TCGA data showed that elevated CASP9 expression was significantly associated with poorer overall survival in patients with RCC. In 786-O and ACHN cells, chronic exposure to an environmentally relevant concentration of BaP significantly increased CASP9 protein stability without altering its mRNA expression, suggesting post-transcriptional regulation. Collectively, these findings identify shared molecular targets of EDCs across urogenital cancers and provide new mechanistic insight into EDC-driven tumor progression, prioritizing potential biomarkers and therapeutic targets for environmentally related malignancies.
- Open Access
- 16 January 2026
- Published by Wiley in Andrologia
- Vol. 2026 (1)
Seminal Extracellular Vesicles LGALS3BP as a Potential Biomarker of Varicocele‐Associated Infertility in TMT‐Based Quantitative Proteomic Analysis
The proteomic analysis of seminal plasma (SP) is a powerful tool for screening and identifying potential novel biomarkers of male infertility. However, the proteomic composition of seminal extracellular (SE) vesicles in varicocele (VC) is still poorly characterized. The main objective of the present study was to compare the proteome of SEs between infertile men with VC and fertile men without VC and to reveal differentially expressed SEs proteins (DESEPs) that can serve as potential novel biomarkers of VC‐associated infertility. SEs were isolated and purified from SP, and SEs proteins were extracted and labeled with TMT and analyzed by high‐resolution LC‐MS/MS. A total of 1457 proteins were quantitatively identified in these SEs samples. Of these proteins, 175 DESEPs (76 upregulated and 99 downregulated) were identified. Bioinformatics analysis indicated that the molecular functions and biological processes of these DESEPs were involved in metabolism, cell growth and/or maintenance, energy pathways, transport, and cell activation. Among these DESEPs of interest, PGK2 and LGALS3BP were validated by Western blotting. The expression level of the SEs LGALS3BP was also determined by ELISA. A significant positive association was observed between the concentration of SEs LGALS3BP and clinical characteristics. Moreover, receiver operating characteristic (ROC) curve analysis showed that SEs LGALS3BP had better predictive efficacy than seminal LGALS3BP as a potential diagnostic biomarker of VC‐associated infertility. Differences in the SEs protein profiles indicate that DESEPs may serve as potential biomarkers for VC‐associated infertility.
- 16 January 2026
- Published by Wiley in Andrologia
- Vol. 2026 (1)
Open AccessSeminal Extracellular Vesicles LGALS3BP as a Potential Biomarker of Varicocele‐Associated Infertility in TMT‐Based Quantitative Proteomic Analysis
The proteomic analysis of seminal plasma (SP) is a powerful tool for screening and identifying potential novel biomarkers of male infertility. However, the proteomic composition of seminal extracellular (SE) vesicles in varicocele (VC) is still poorly characterized. The main objective of the present study was to compare the proteome of SEs between infertile men with VC and fertile men without VC and to reveal differentially expressed SEs proteins (DESEPs) that can serve as potential novel biomarkers of VC‐associated infertility. SEs were isolated and purified from SP, and SEs proteins were extracted and labeled with TMT and analyzed by high‐resolution LC‐MS/MS. A total of 1457 proteins were quantitatively identified in these SEs samples. Of these proteins, 175 DESEPs (76 upregulated and 99 downregulated) were identified. Bioinformatics analysis indicated that the molecular functions and biological processes of these DESEPs were involved in metabolism, cell growth and/or maintenance, energy pathways, transport, and cell activation. Among these DESEPs of interest, PGK2 and LGALS3BP were validated by Western blotting. The expression level of the SEs LGALS3BP was also determined by ELISA. A significant positive association was observed between the concentration of SEs LGALS3BP and clinical characteristics. Moreover, receiver operating characteristic (ROC) curve analysis showed that SEs LGALS3BP had better predictive efficacy than seminal LGALS3BP as a potential diagnostic biomarker of VC‐associated infertility. Differences in the SEs protein profiles indicate that DESEPs may serve as potential biomarkers for VC‐associated infertility.
- Open Access
- 12 November 2025
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 306, 119383
Methylparaben and propylparaben promote bladder cancer invasion via MMP2 and PPARG modulation
- 12 November 2025
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 306, 119383
Open AccessMethylparaben and propylparaben promote bladder cancer invasion via MMP2 and PPARG modulation
- Open Access
- 22 September 2023
- Published by Medknow in Asian Journal of Andrology
- Vol. 25 (6) , 758
Corrigendum to “MicroRNA-27a-mediated repression of cysteine-rich secretory protein 2 translation in asthenoteratozoospermic patients”
- 22 September 2023
- Published by Medknow in Asian Journal of Andrology
- Vol. 25 (6) , 758
Open AccessCorrigendum to “MicroRNA-27a-mediated repression of cysteine-rich secretory protein 2 translation in asthenoteratozoospermic patients”
- Open Access
Hub gene associated with prognosis in bladder cancer is a novel therapeutic target
Objective: Bladder cancer is a clinical and social conundrum due to its high incidence and recurrence rate. It is urgent to find new targets for the diagnosis and treatment of bladder cancer and improve the prognosis and survival rate of bladder cancer patients. We sought a prognosis-related gene, built related models of evaluated bladder cancer and identified the function of the hub gene in bladder cancer. Methods: We downloaded the data of bladder cancer patients from the TCGA database, and used differentially expressed genes (DEGs), copy number variation (CNV) and survival analysis to scan the hub genes associated with prognosis in bladder cancer. Then, multi-factor cox regression was used to obtain the bladder cancer prognosis correlation model. Then, we analyzed the relationship between the expression of hub gene and immune microenvironment of bladder cancer. The relationship between the expression of hub gene and prognosis in bladder cancer patients was verified by immunohistochemistry. Cell proliferation assay and drug sensitivity test in vivo were used to verify the inhibition of bladder cancer by targeted inhibitors. Results: In bladder cancer, we screened seven hub genes (ACLY, CNP, NKIRAS2, P3H4, PDIA6, VPS25 and XPO1) associated with survival. Moreover, the multifactor regression model constructed with hub gene can well distinguish the prognosis of bladder cancer. Hub gene is mostly associated with immune microenvironment. Immunohistochemical results basically confirmed the importance of XPO1 in bladder cancer. Selinexor (an inhibitor of XPO1) could effectively inhibit the proliferation of bladder cancer in the cell proliferation experiments by CCK-8 assays and it could suppress the growth of bladder cancer in mouse bladder cancer model. Conclusions: In this study, a prognostic model with seven hub genes has provided great help for the prognosis prediction of bladder cancer patients. And XPO1 is an important target affecting the prognosis of bladder cancer, and inhibition of XPO1 can effectively inhibit bladder cancer proliferation and growth.
Open AccessHub gene associated with prognosis in bladder cancer is a novel therapeutic target
Objective: Bladder cancer is a clinical and social conundrum due to its high incidence and recurrence rate. It is urgent to find new targets for the diagnosis and treatment of bladder cancer and improve the prognosis and survival rate of bladder cancer patients. We sought a prognosis-related gene, built related models of evaluated bladder cancer and identified the function of the hub gene in bladder cancer. Methods: We downloaded the data of bladder cancer patients from the TCGA database, and used differentially expressed genes (DEGs), copy number variation (CNV) and survival analysis to scan the hub genes associated with prognosis in bladder cancer. Then, multi-factor cox regression was used to obtain the bladder cancer prognosis correlation model. Then, we analyzed the relationship between the expression of hub gene and immune microenvironment of bladder cancer. The relationship between the expression of hub gene and prognosis in bladder cancer patients was verified by immunohistochemistry. Cell proliferation assay and drug sensitivity test in vivo were used to verify the inhibition of bladder cancer by targeted inhibitors. Results: In bladder cancer, we screened seven hub genes (ACLY, CNP, NKIRAS2, P3H4, PDIA6, VPS25 and XPO1) associated with survival. Moreover, the multifactor regression model constructed with hub gene can well distinguish the prognosis of bladder cancer. Hub gene is mostly associated with immune microenvironment. Immunohistochemical results basically confirmed the importance of XPO1 in bladder cancer. Selinexor (an inhibitor of XPO1) could effectively inhibit the proliferation of bladder cancer in the cell proliferation experiments by CCK-8 assays and it could suppress the growth of bladder cancer in mouse bladder cancer model. Conclusions: In this study, a prognostic model with seven hub genes has provided great help for the prognosis prediction of bladder cancer patients. And XPO1 is an important target affecting the prognosis of bladder cancer, and inhibition of XPO1 can effectively inhibit bladder cancer proliferation and growth.
- Open Access
- 12 April 2023
- Published by Springer Nature in Research Square
Construction and experimental validation of a macrophage cell senescence-related gene signature to evaluate the prognosis, immunotherapeutic sensitivity, and chemotherapy response in bladder cancer
Tumor-associated macrophages (TAMs) are pivotal components of tumor microenvironment (TME), and senescent TAMs contribute to the alternation of the profiles of TME. However, the latent biological mechanisms and the prognosis value of senescent macrophages are largely unknown, especially in bladder cancer (BLCA). Based on the single-cell RNA sequencing of a primary BLCA sample, 23 macrophage-related genes were identified. Genomic difference analysis, LASSO, and Cox regression were used to develop the risk model. TCGA-BLCA cohort (n = 406) was utilized as the training cohort, while three independent cohorts (n = 90, n = 221, n = 165) from Gene Expression Omnibus, clinical samples from the local hospital (n = 27), and in vitro cell experiments were used for external validation. Aldo-keto reductase family 1 member B (AKR1B1), inhibitor of DNA binding 1 (ID1), and transforming growth factor beta 1 (TGFB1I1) were determined and included in the predictive model. The model serves as a promising tool to evaluate the prognosis in BLCA (pooled hazard ratio = 2.51, 95% confidence interval = [1.43; 4.39]). The model was also effective for the prediction of immunotherapeutic sensitivity and chemotherapy treatment outcomes, which were confirmed by IMvigor210 cohort (P < 0.01) and GDSC dataset, respectively. 27 BLCA samples from the local hospital proved that the risk model was associated with the malignant degree (P < 0.05). At last, the human macrophage THP-1 and U937 cells were treated with H2O2 to mimic macrophage senescent process, and the expressions of the molecules in the model were detected (all P < 0.05). Overall, a macrophage cell senescence-relatedgene signature was constructed to predict the prognosis, immunotherapeutic response, and chemotherapy sensitivity, providing novel insights to uncover the underlying mechanisms.
- 12 April 2023
- Published by Springer Nature in Research Square
Open AccessConstruction and experimental validation of a macrophage cell senescence-related gene signature to evaluate the prognosis, immunotherapeutic sensitivity, and chemotherapy response in bladder cancer
Tumor-associated macrophages (TAMs) are pivotal components of tumor microenvironment (TME), and senescent TAMs contribute to the alternation of the profiles of TME. However, the latent biological mechanisms and the prognosis value of senescent macrophages are largely unknown, especially in bladder cancer (BLCA). Based on the single-cell RNA sequencing of a primary BLCA sample, 23 macrophage-related genes were identified. Genomic difference analysis, LASSO, and Cox regression were used to develop the risk model. TCGA-BLCA cohort (n = 406) was utilized as the training cohort, while three independent cohorts (n = 90, n = 221, n = 165) from Gene Expression Omnibus, clinical samples from the local hospital (n = 27), and in vitro cell experiments were used for external validation. Aldo-keto reductase family 1 member B (AKR1B1), inhibitor of DNA binding 1 (ID1), and transforming growth factor beta 1 (TGFB1I1) were determined and included in the predictive model. The model serves as a promising tool to evaluate the prognosis in BLCA (pooled hazard ratio = 2.51, 95% confidence interval = [1.43; 4.39]). The model was also effective for the prediction of immunotherapeutic sensitivity and chemotherapy treatment outcomes, which were confirmed by IMvigor210 cohort (P < 0.01) and GDSC dataset, respectively. 27 BLCA samples from the local hospital proved that the risk model was associated with the malignant degree (P < 0.05). At last, the human macrophage THP-1 and U937 cells were treated with H2O2 to mimic macrophage senescent process, and the expressions of the molecules in the model were detected (all P < 0.05). Overall, a macrophage cell senescence-relatedgene signature was constructed to predict the prognosis, immunotherapeutic response, and chemotherapy sensitivity, providing novel insights to uncover the underlying mechanisms.
- Open Access
- 1 March 2023
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 12 (3) , 572-584
Overexpression of SPHK1 associated with targeted therapy resistance in predicting poor prognosis in renal cell carcinoma
Original Article Overexpression of SPHK1 associated with targeted therapy resistance in predicting poor prognosis in renal cell carcinoma Ji-Ming Bao, Xi Zhi, Hao-Yu Yuan, Tao-Yi Chen, Ming-Kun Chen, Jun-Hao Zhou, Kang-Yi Xue, Jian-Kun Yang, Cun-Dong Liu
- 1 March 2023
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 12 (3) , 572-584
Open AccessOverexpression of SPHK1 associated with targeted therapy resistance in predicting poor prognosis in renal cell carcinoma
Original Article Overexpression of SPHK1 associated with targeted therapy resistance in predicting poor prognosis in renal cell carcinoma Ji-Ming Bao, Xi Zhi, Hao-Yu Yuan, Tao-Yi Chen, Ming-Kun Chen, Jun-Hao Zhou, Kang-Yi Xue, Jian-Kun Yang, Cun-Dong Liu